178 related articles for article (PubMed ID: 24876147)
1. [Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up].
Gendron N; Belhouachi N; Morel V; Azgui Z; Maloum K; Nguyen-Khac F; Cayuela JM; Davi F; Merle-Béral H; Chapiro E
Ann Biol Clin (Paris); 2014; 72(3):359-66. PubMed ID: 24876147
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
[TBL] [Abstract][Full Text] [Related]
3. E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukemia resistant to imatinib.
Li C; Wang Y; Xu D; Zhang P; Ding X; Zhang N; Xiao M; Huang L; Meng L
Clin Lab; 2015; 61(1-2):183-6. PubMed ID: 25807654
[TBL] [Abstract][Full Text] [Related]
4. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
Branford S; Kim DW; Soverini S; Haque A; Shou Y; Woodman RC; Kantarjian HM; Martinelli G; Radich JP; Saglio G; Hochhaus A; Hughes TP; Müller MC
J Clin Oncol; 2012 Dec; 30(35):4323-9. PubMed ID: 23109697
[TBL] [Abstract][Full Text] [Related]
5. Optimal Response in a Patient With CML Expressing
Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
Sazawal S; Chikkara S; Singh K; Chaubey R; Chandra D; Mishra P; Mahapatra M; Seth T; Saxena R
Ann Diagn Pathol; 2017 Apr; 27():24-27. PubMed ID: 28325357
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations.
Inokuchi K; Nakayama K; Tauchi T; Takaku T; Yokose N; Yamaguchi H; Kumagai T; Komatsu N; Ohyashiki K
Leuk Res; 2018 Feb; 65():74-79. PubMed ID: 29310021
[TBL] [Abstract][Full Text] [Related]
8. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
Qin YZ; Jiang Q; Jiang H; Lai YY; Shi HX; Chen WM; Yu L; Huang XJ
Br J Haematol; 2018 Sep; 182(5):693-700. PubMed ID: 29974949
[TBL] [Abstract][Full Text] [Related]
10. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
11. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
[TBL] [Abstract][Full Text] [Related]
12. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
13. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
Rostami G; Hamid M; Jalaeikhoo H
Gene; 2017 Sep; 627():202-206. PubMed ID: 28627443
[TBL] [Abstract][Full Text] [Related]
14. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
Machova Polakova K; Kulvait V; Benesova A; Linhartova J; Klamova H; Jaruskova M; de Benedittis C; Haferlach T; Baccarani M; Martinelli G; Stopka T; Ernst T; Hochhaus A; Kohlmann A; Soverini S
J Cancer Res Clin Oncol; 2015 May; 141(5):887-99. PubMed ID: 25367136
[TBL] [Abstract][Full Text] [Related]
15. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
[TBL] [Abstract][Full Text] [Related]
16. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Kitamura H; Tabe Y; Ai T; Tsuchiya K; Yuri M; Misawa S; Horii T; Kawaguchi A; Ohsaka A; Kimura S
PLoS One; 2019; 14(3):e0207170. PubMed ID: 30835732
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
Xue M; Wang Q; Huo L; Wen L; Yang X; Wu Q; Pan J; Cen J; Ruan C; Wu D; Chen S
Leuk Lymphoma; 2019 Dec; 60(12):3051-3057. PubMed ID: 31258010
[TBL] [Abstract][Full Text] [Related]
18. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
[TBL] [Abstract][Full Text] [Related]
19. Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion.
Crampe M; Garry J; Langabeer SE; Murphy PT
Hematol Oncol Stem Cell Ther; 2016 Dec; 9(4):168-169. PubMed ID: 27352262
[No Abstract] [Full Text] [Related]
20. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
McCarron SL; Langabeer SE; Bolger K; Haslam K; Crampe M; Kelly J; Morrell R
Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
